Olav Hellebø, co-founder of Palma Biotech SL in Spain and former chief executive of Clavis Pharma ASA, has joined the board of directors of Pharmalink AB, a specialty pharmaceutical company based in Stockholm. Mr Hellebø is joined on the board by Ann-Tove Kongsnes, an investment director at Investinor, and Hilde Furberg, senior vice president rare diseases for Europe, the Middle East and Africa at Genzyme (Sanofi SA). Pharmalink has products in late-stage development for IgA nephropathy and for use in cancer patients, prior to haematopoietic stem cell transplantation.
Pharmalink announced the appointment on 3 July 2014.
Copyright 2014 Evernow Publishing Ltd